Please enable JS

ARTICLES & TESTIMONIALS

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

FDA advisory committee unanimously recommends approval of biosimilar to Enbrel – Perspective by Seth Ginsberg

Jul 15/50SN Staff/ GHLF in the news

The overall aim of biosimilar is to help contribute toward the reduction of cost for patients.

READ MORE

Biosimilar Confidence: Patient Perspectives on a New Medication Class – Seth Ginsberg

Jul 15/50SN Staff/ GHLF in the news

Imagine you’ve been living with rheumatoid arthritis for more than ten years.

READ MORE

Victory in Missouri

Jun 09/50SN Staff/ Victories

At its core, HB 1366 boils down to two words: Trust and transparency.

READ MORE

GHLF Supports OH HB 505

Apr 19/50SN Staff/ Letters and Testimony

HB 505 takes positive steps toward updating Ohio law to cover biologics and biosimilars in a
way that protects patients. As you know, unlike traditional chemical drugs, biologics are unique,
complex structures made from living cells that are not easily replicated. A small change or
difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.

READ MORE

Victory in Oregon

Apr 08/50SN Staff/ Victories

Last year in March, 50-State Network advocate Anna Marie Meyer testified before the Oregon House of Representatives Committee on Health Care in opposition to HB 2026.

READ MORE